SPY382.33-9.44 -2.41%
DIA313.98-5.55 -1.74%
IXIC13,119.43-478.54 -3.52%

BRIEF-Gilead Sciences Reports Q4 Non-GAAP Earnings Per Share Of $2.19

· 02/04/2021 16:16
BRIEF-Gilead Sciences Reports Q4 Non-GAAP Earnings Per Share Of $2.19

- Gilead Sciences Inc GILD.O:

  • GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS

  • Q4 NON-GAAP EARNINGS PER SHARE $2.19

  • Q4 EARNINGS PER SHARE $1.23

  • SEES FY 2021 NON-GAAP EARNINGS PER SHARE $6.75 TO $7.45

  • Q4 EARNINGS PER SHARE ESTIMATE $2.15 -- REFINITIV IBES DATA

  • SEES 2021 PRODUCT SALES INCLUDING VEKLURY OF $23.7 BILLION TO $25.1 BILLION

  • SEES FULL YEAR 2021 OPERATING EXPENSES FLAT TO LOW SINGLE-DIGIT PERCENTAGE DECLINE

  • VEKLURY SALES WERE $1.9 BILLION FOR Q4

  • FY2021 EARNINGS PER SHARE VIEW $6.85, REVENUE VIEW $24.27 BILLION -- REFINITIV IBES DATA

  • QTRLY TOTAL REVENUES $7,421 MILLION VERSUS $5,879 MILLION

  • QTRLY PRODUCT SALES INCREASED 26% TO $7.3 BILLION, PRIMARILY DUE TO VEKLURY

  • COVID-19 PANDEMIC CONTINUES TO IMPACT GILEAD'S BUSINESS AND BROADER MARKET DYNAMICS, INCLUDING HCV AND HIV MARKET VOLUME

  • EXPECTS A GRADUAL RECOVERY IN UNDERLYING MARKET DYNAMICS STARTING Q2 2021.

  • EXPECTS PATIENTS WITH HCV WILL BEGIN TO INITIATE TREATMENT BY Q2 2021.

  • TRUVADA AND ATRIPLA SALES ARE EXPECTED TO CONTINUE TO DECLINE IN Q1 2021

  • TRUVADA AND ATRIPLA SALES ARE ALSO EXPECTED TO CONTINUE TO DECLINE BEYOND Q1 2021

  • BIKTARVY, TRODELVY, VEMLIDY AND CELL THERAPY ARE EXPECTED TO BE KEY GROWTH DRIVERS IN 2021

  • SEES FULL YEAR 2021 VEKLURY SALES $2,000 MILLION - $3,000 MILLION

  • Q4 REVENUE VIEW $7.33 BILLION -- REFINITIV IBES DATA

  • SEES FY 2021 GAAP DILUTED EPS $5.25 - $5.95

Source text for Eikon: ID:nBw239Yka

Further company coverage: GILD.O


((Reuters.Briefs@thomsonreuters.com;))